The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft
dc.contributor.author | Kiefer, J. A. | en_US |
dc.contributor.author | Vessella, Robert L. | en_US |
dc.contributor.author | Quinn, Janna E. | en_US |
dc.contributor.author | Odman, Austin M. | en_US |
dc.contributor.author | Zhang, Jian | en_US |
dc.contributor.author | Keller, Evan T. | en_US |
dc.contributor.author | Kostenuik, P. J. | en_US |
dc.contributor.author | Dunstan, C. R. | en_US |
dc.contributor.author | Corey, E. | en_US |
dc.date.accessioned | 2006-09-08T20:30:09Z | |
dc.date.available | 2006-09-08T20:30:09Z | |
dc.date.issued | 2004-12 | en_US |
dc.identifier.citation | Kiefer, J. A.; Vessella, R. L.; Quinn, J. E.; Odman, A. M.; Zhang, J.; Keller, E. T.; Kostenuik, P. J.; Dunstan, C. R.; Corey, E.; (2004). "The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft." Clinical & Experimental Metastasis 21(5): 381-387. <http://hdl.handle.net/2027.42/42587> | en_US |
dc.identifier.issn | 0262-0898 | en_US |
dc.identifier.issn | 1573-7276 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/42587 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15672862&dopt=citation | en_US |
dc.description.abstract | Osteoprotegerin (OPG) plays a central role in controlling bone resorption. Exogenous administration of OPG has been shown to be effective in preventing osteolysis and limiting the growth of osteolytic metastasis. The objective of this study was to investigate the effects of OPG on osteoblastic prostate cancer (CaP) metastases in an animal model. LuCaP 23.1 cells were injected intra-tibially and Fc-OPG (6.0 mg/kg) was administered subcutaneously three times a week starting either 24 hours prior to cell injection (prevention regimen) or at 4 weeks post-injection (treatment regimen). Changes in bone mineral density at the tumor site were determined by dual x-ray absorptiometry. Tumor growth was monitored by evaluating serum prostate specific antigen (PSA). Fc-OPG did not inhibit establishment of osteoblastic bone lesions of LuCaP 23.1, but it decreased growth of the tumor cells, as determined by decreases in serum PSA levels of 73.0 ± 44.3% ( P < 0.001) and 78.3 ± 25.3% ( P < 0.001) under the treatment and prevention regimens, respectively, compared to the untreated tumor-bearing animals. Administration of Fc-OPG decreased the proliferative index by 35.0% ( P = 0.1838) in the treatment group, and 75.2% ( P = 0.0358) in the prevention group. The results of this study suggest a potential role for OPG in the treatment of established osteoblastic CaP bone metastases. | en_US |
dc.format.extent | 268284 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Cancer Research | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Hematology | en_US |
dc.subject.other | Surgical Oncology | en_US |
dc.subject.other | Bone Metastases | en_US |
dc.subject.other | Bone Remodeling | en_US |
dc.subject.other | Osteoblast | en_US |
dc.subject.other | Osteoprotegerin | en_US |
dc.subject.other | Prostate Cancer | en_US |
dc.subject.other | PSA | en_US |
dc.title | The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pathology, , University of Michigan, , , Ann Arbor, , Michigan, , USA, | en_US |
dc.contributor.affiliationum | Department of Pathology, , University of Michigan, , , Ann Arbor, , Michigan, , USA, | en_US |
dc.contributor.affiliationother | Department of Urology, , University of Washington School of Medicine, , , Seattle, , Washington, , USA, | en_US |
dc.contributor.affiliationother | Department of Urology, , University of Washington School of Medicine, , , Seattle, , Washington, , USA, ; VA Medical Center, , , Seattle, , Washington, , USA, | en_US |
dc.contributor.affiliationother | Department of Urology, , University of Washington School of Medicine, , , Seattle, , Washington, , USA, | en_US |
dc.contributor.affiliationother | Department of Urology, , University of Washington School of Medicine, , , Seattle, , Washington, , USA, | en_US |
dc.contributor.affiliationother | Amgen, Inc., , , Thousand Oaks, , California, , USA, | en_US |
dc.contributor.affiliationother | Amgen, Inc., , , Thousand Oaks, , California, , USA, | en_US |
dc.contributor.affiliationother | Department of Urology, , University of Washington School of Medicine, , , Seattle, , Washington, , USA, ; Department of Urology, , University of Washington, , , 1959 NE Pacific St. HSB I-340, , Seattle, , Mailstop 356510, , 98195, , WA, , USA, | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 15672862 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/42587/1/10585_2004_Article_2869.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s10585-004-2869-0 | en_US |
dc.identifier.source | Clinical & Experimental Metastasis | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.